Hydroxy Chloroquine and Covid in RA Patients

NCT04471649 | Unknown

• 1 other identifier: 002
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

evaluation of the clinical course of COVID-19 in a cohort of patients with rheumatoid arthritis treated with or without hydroxychloroquine.

Conditions

COVID

Keywords

Covid-19; Hydroxy chloroquine; Rheumatoid

Outcome Measures

Primary Outcomes (4)

• Number of patients in need for hospitalization

  Estimate number of patients in need for hospitalization

  through study completion an average 12 weeks

• Length of hospitalization and ICU admission

  Calculate the number of days that the patients stayed at the hospital and how many patients admitted to ICU

  through study completion an average 12 weeks

• The need for mechanical ventilation

  Calculate the number of patients who received mechanical ventilation

  through study completion an average 12 weeks

• Severity of COVID-19 disease

  WHO clinical management Covid19 interim guidance disease severity Algorithm

  through study completion an average 12 weeks

Study Arms (2)

Experimental

Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.

Active Comparator

Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

To Evaluaye the clinical course of COVID-19 in a cohort of patients with rheumatoid arthritis treated with or without hydroxychloroquine: Data will be taken from the medical records of patients with rheumatoid arthritis in the outpatient clinic of the Rheumatology and Rehabilitation department, Tanta University hospital, Tanta, Egypt. A) Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen. b) Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen. Primary Outcome Measures: 1\. Impact of hydroxychloroquine on the clinical course of Covid-19 in the hydroxychloroquine group compared to the non- hydroxychloroquine group. Data will be collected and analyzed from patient medical records.

You may qualify if:

• Adult patients with rheumatoid arthritis superinfected with Covid-19

You may not qualify if:

• Insufficient data are available in the medical record.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University Hospital

Tanta, 31527, Egypt

RECRUITING

Related Publications (1)

• Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.

  PMID: 32173110 BACKGROUND

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Asem Elfert, Prof

  tanta university faculty of medicine

  STUDY CHAIR

Central Study Contacts

Mohammed Hassan Abu-Zaid, PhD

CONTACT

+201006773622; Drmhassan113@yahoo.com

Samar Tabra, PhD

CONTACT

+201007501572; Dr_stabra_113@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 7, 2020
• First Posted: July 15, 2020
• Study Start: June 15, 2020
• Primary Completion: October 1, 2020
• Study Completion: November 1, 2020
• Last Updated: September 9, 2020

Record last verified: 2020-09

Locations

EG (1)